Honokiol for Alzheimer's Disease
Also known as: Magnolia bark extract
Honokiol crosses the BBB and inhibits amyloid aggregation while activating SIRT3 for mitochondrial protection.
Mechanism of Action
Honokiol activates SIRT3, enhancing mitochondrial SOD2 activity and reducing oxidative stress. It inhibits Aβ aggregation, suppresses BACE1, reduces tau phosphorylation through GSK3β inhibition, and activates AMPK for autophagy induction.
General mechanism: Biphenol from magnolia bark. SIRT3 activator, NF-κB/STAT3 inhibitor, mTOR suppressor. Crosses BBB/BSCB.
Current Evidence
Preclinical AD models show cognitive improvement and reduced pathology. SIRT3 activation is a unique mechanism among natural compounds. BBB penetrance confirmed.
Clinical Status: Preclinical. BBB-penetrant natural SIRT3 activator.
Safety Profile
Safe in preclinical studies. Long history of use in traditional medicine. Mild sedative effects. Limited human safety data at therapeutic doses.
Key Research Questions
- Can honokiol's SIRT3 activation provide sustained neuroprotection in AD?
- Does honokiol synergize with anti-amyloid antibodies?